Sudden Cardiac Arrest after Daratumumab Infusion

Aditya Jandial; Kundan Mishra; Gaurav Prakash; Pankaj Malhotra

doi:10.4103/ijmpo.ijmpo_28_18

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(02): 301-303
DOI: 10.4103/ijmpo.ijmpo_28_18

Letter to Editor

Sudden Cardiac Arrest after Daratumumab Infusion

Authors

Aditya Jandial

Department of Internal Medicine, Division of Clinical Hematology, PGIMER, Chandigarh, India
Kundan Mishra

Department of Internal Medicine, Division of Clinical Hematology, PGIMER, Chandigarh, India
Gaurav Prakash

Department of Internal Medicine, Division of Clinical Hematology, PGIMER, Chandigarh, India
Pankaj Malhotra

Department of Internal Medicine, Division of Clinical Hematology, PGIMER, Chandigarh, India

Abstract

Volltext

Referenzen

References
1 Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R. et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist 2016. pii: theoncologist. 2016-0104
2 Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551-60
3 McKeage K. Daratumumab:First global approval. Drugs 2016; 76: 275-81
4 Yanamandra U, Khattry N, Kumar S, Raje N, Jain A, Jagannath S. et al. Consensus in the management of multiple myeloma in india at myeloma state of the art 2016 conference. Indian J Hematol Blood Transfus 2017; 33: 15-21
5 Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S. et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016; 128: 37-44
6 Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754-66
7 Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 1319-31
8 Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK. et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol 2017; 92: 1146-55
9 Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130: 974-81
10 Rosa GM, Gigli L, Tagliasacchi MI, Di Iorio C, Carbone F, Nencioni A. et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest 2016; 46: 264-84